IT8847693A0 - Fenil carbammato farmacologicamente attivo, suo procedimento di preparazione e composizione farmaceutica che lo contiene - Google Patents

Fenil carbammato farmacologicamente attivo, suo procedimento di preparazione e composizione farmaceutica che lo contiene

Info

Publication number
IT8847693A0
IT8847693A0 IT8847693A IT4769388A IT8847693A0 IT 8847693 A0 IT8847693 A0 IT 8847693A0 IT 8847693 A IT8847693 A IT 8847693A IT 4769388 A IT4769388 A IT 4769388A IT 8847693 A0 IT8847693 A0 IT 8847693A0
Authority
IT
Italy
Prior art keywords
pharmaceutical composition
pharmacologically active
preparation procedure
phenyl carbamate
active phenyl
Prior art date
Application number
IT8847693A
Other languages
English (en)
Other versions
IT1219853B (it
Inventor
Enz Albert
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT8847693(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IT8847693A0 publication Critical patent/IT8847693A0/it
Application granted granted Critical
Publication of IT1219853B publication Critical patent/IT1219853B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IT47693/88A 1987-03-04 1988-03-04 Fenil carbammato farmacologicamente attivo,suo procedimento di preparazione e composizione farmaceutica che lo contiene IT1219853B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (2)

Publication Number Publication Date
IT8847693A0 true IT8847693A0 (it) 1988-03-04
IT1219853B IT1219853B (it) 1990-05-24

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
IT47693/88A IT1219853B (it) 1987-03-04 1988-03-04 Fenil carbammato farmacologicamente attivo,suo procedimento di preparazione e composizione farmaceutica che lo contiene

Country Status (29)

Country Link
US (1) US5602176A (it)
JP (3) JP2625478B2 (it)
KR (1) KR0133686B1 (it)
AT (1) AT394190B (it)
AU (1) AU618949B2 (it)
BE (1) BE1001467A3 (it)
CA (1) CA1307003C (it)
CH (1) CH675720A5 (it)
CS (1) CS411091A3 (it)
CY (1) CY1735A (it)
DK (1) DK175762B1 (it)
ES (1) ES2010527A6 (it)
FI (1) FI89165C (it)
FR (1) FR2611707B1 (it)
GB (1) GB2203040C (it)
GR (1) GR1000023B (it)
HK (1) HK110093A (it)
HU (1) HU201906B (it)
IE (1) IE61714B1 (it)
IL (1) IL85609A (it)
IT (1) IT1219853B (it)
LU (2) LU87150A1 (it)
MY (1) MY103225A (it)
NL (1) NL195004C (it)
NZ (1) NZ223714A (it)
PT (1) PT86875B (it)
SA (1) SA93140384B1 (it)
SE (1) SE8800731A0 (it)
ZA (1) ZA881584B (it)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
CA2187086A1 (en) * 1994-04-15 1995-10-26 Masaomi Iyo A pharmaceutical composition for therapeutically treating tardive dyskinesia and uses therof
HU226526B1 (en) * 1996-12-18 2009-03-30 Teva Pharma Phenylethylamine derivatives, use of them for preparation of pharmaceutical compositions and the pharmaceutical compositions comprising them
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
PT966435E (pt) 1996-12-18 2005-06-30 Yissum Res Dev Co Derivados aminoindano
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
WO2000019985A2 (en) 1998-10-01 2000-04-13 Novartis Ag New sustained release oral formulations
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
EP1137414B1 (en) * 1998-12-11 2005-10-12 Bonnie M. Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
JP2006506378A (ja) * 2002-10-24 2006-02-23 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン １−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
WO2005042475A2 (en) * 2003-10-21 2005-05-12 Sention, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
RU2393148C2 (ru) * 2004-11-08 2010-06-27 Эмкюр Фармасьютикалз Лимитед Способ получения (s)-3-[(1-диметиламино)этил]-фенил-n-этил-n-метил-карбамата
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
ATE546202T1 (de) 2005-09-15 2012-03-15 Sony Computer Entertainment Inc Kabelloser videospielcontroller und verfahren zum betreiben des kabellosen videospielcontrollers
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CA2634166C (en) * 2005-12-09 2016-03-29 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
AU2008214380A1 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20090048229A1 (en) * 2007-07-18 2009-02-19 Rupniak Nadia M J Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
CN101910110B (zh) * 2008-01-10 2013-05-22 上海医药工业研究院 利凡斯的明的制备方法、其中间体以及中间体的制备方法
WO2010023535A1 (en) 2008-08-25 2010-03-04 Jubilant Organosys Limited A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
BR112012017168B1 (pt) 2009-12-22 2022-03-15 Luye Pharma Ag Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CA2789014C (en) * 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
RU2603486C2 (ru) 2010-03-29 2016-11-27 Новартис Аг КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ АМИЛОИДНЫЙ ПЕПТИД Аβ-1-6, ПРИСОЕДИНЕННЫЙ К ВИРУСОПОДОБНОЙ ЧАСТИЦЕ И АДЪЮВАНТУ
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011159910A2 (en) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
EA027840B1 (ru) 2010-11-15 2017-09-29 Эйджинбайо, Инк. Производные пиридазина, композиции и способы лечения когнитивного нарушения
EP2468274B1 (de) 2010-12-14 2015-07-01 Acino AG Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
EP2711002A4 (en) 2011-05-20 2014-10-29 Sk Chemicals Co Ltd PLASTER WITH RIVASTIGMIN
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
WO2013031992A1 (ja) 2011-08-31 2013-03-07 積水メディカル株式会社 貼付剤
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
MX391314B (es) 2013-12-20 2025-03-21 Agenebio Inc Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro cognitivo.
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
MX392119B (es) 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法
WO2025038382A1 (en) 2023-08-11 2025-02-20 Momentive Performance Materials Inc. Pharmaceutical adhesive compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPS63238054A (ja) 1988-10-04
HK110093A (en) 1993-10-29
FR2611707A1 (fr) 1988-09-09
FI880972A0 (fi) 1988-03-02
ZA881584B (en) 1989-11-29
MY103225A (en) 1993-05-29
GB2203040C (en) 2014-07-30
JP2625478B2 (ja) 1997-07-02
CA1307003C (en) 1992-09-01
NL195004B (nl) 2003-07-01
US5602176A (en) 1997-02-11
GB2203040B (en) 1990-10-24
NL8800436A (nl) 1988-10-03
IL85609A0 (en) 1988-08-31
ES2010527A6 (es) 1989-11-16
ATA55188A (de) 1991-08-15
FI89165B (fi) 1993-05-14
IL85609A (en) 1992-07-15
PT86875B (pt) 1992-05-29
DK112588A (da) 1988-09-05
FR2611707B1 (fr) 1990-04-20
KR880011088A (ko) 1988-10-26
SE8800731L (sv) 1988-09-05
GR1000023B (el) 1990-01-31
JPH09165362A (ja) 1997-06-24
SE8800731D0 (sv) 1988-03-02
PT86875A (pt) 1988-04-01
IE880583L (en) 1988-09-04
GB8804888D0 (en) 1988-03-30
FI880972L (fi) 1988-09-05
JPH09118617A (ja) 1997-05-06
AU1255488A (en) 1988-09-08
GB2203040A (en) 1988-10-12
LU87150A1 (fr) 1988-11-17
NZ223714A (en) 1994-05-26
SE8800731A0 (sv) 1988-09-05
SA93140384B1 (ar) 2006-04-04
HUT49325A (en) 1989-09-28
AT394190B (de) 1992-02-10
CH675720A5 (it) 1990-10-31
BE1001467A3 (fr) 1989-11-07
IE61714B1 (en) 1994-11-30
KR0133686B1 (ko) 1998-04-21
NL195004C (nl) 2003-11-04
FI89165C (fi) 1993-08-25
CY1735A (en) 1994-06-03
CS411091A3 (en) 1992-12-16
HU201906B (en) 1991-01-28
AU618949B2 (en) 1992-01-16
IT1219853B (it) 1990-05-24
LU90297I2 (fr) 1998-12-07
JP2859225B2 (ja) 1999-02-17
DK112588D0 (da) 1988-03-02
GR880100125A (en) 1989-01-31
DK175762B1 (da) 2005-02-14

Similar Documents

Publication Publication Date Title
IT8847693A0 (it) Fenil carbammato farmacologicamente attivo, suo procedimento di preparazione e composizione farmaceutica che lo contiene
IT8947701A0 (it) Derivato di piperazina o suo sale, procedimento per produrlo e composizione farmaceutica che lo contiene come ingrediente attivo
FI904444A0 (fi) Aktiva limkompositioner.
KR920701213A (ko) 메틸렌디포스폰산 화합물 및 그것을 유효성분으로 하는 항염증제
ITMI911147A1 (it) Composto ad attivita' terapeutica, sua preparazione e composizioni farmaceutiche che lo contengono
IT8719165A0 (it) Derivato di acido tiazolidin-4-carbossilico, sua preparazione e composizioni farmaceutiche che lo contengono.
IT8619431A0 (it) Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono, procedimento per prepararlo e intermedio utile in detto procedimento.
DE3768109D1 (de) Pharmazeutische zusammensetzungen.
IT9020615A0 (it) Composto con attivita' vasodilatatrice, procedimento per la sua preparazione e composizione farmaceutiche che lo contengono
IT1190942B (it) Composto ad attivita' analgesica ed antiinfiammatoria,suo procedimento di preparazione e relative composizioni farmaceutiche
IT1237343B (it) Dicloridrato di acetildicarnitina, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
ITMI922241A0 (it) Composto con attivita' vasodilatatrice procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
IT8720226A0 (it) Composto con attivita'vasodilatatrice, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
IT8521409A0 (it) Composto dotato di attivita'ipolipemizzante, procedimento di preparazione e composizioni farmaceutiche che lo contengono.
IT8219652A0 (it) Derivato della propionilglicina, processi per la sua preparazione e composizioni terapeutiche che lo contengono come principio attivo.
IT8748421A0 (it) Composti di cefalosporina,procedimento per produrli e composizioni farmaceutiche che li contengono
ITMI911883A1 (it) Composto con attivita' vasodilatatrice, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
IT8820925A0 (it) Composto con attivita'vasodilatatrice, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
IT8920863A0 (it) Composto con attivita' vasodilatatrice, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
IT8620170A0 (it) Composto con attivita'vasodilatatrice, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
IT8619738A0 (it) Peptide dotato di attivita'antibiotica e composizioni farmaceutiche che lo contengono.
IT1230858B (it) Derivato di idrossiprolina, sua preparazione e composizioni farmaceutiche che lo contengono.
IT8619245A0 (it) Composti ad attivita' mucolitica e composizioni farmaceutiche che licontengono.
BR1100383A (pt) Composto, e, composição farmacêutica
IT8520347A0 (it) Composto con attivita'casodilatatrice, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.

Legal Events

Date Code Title Description
MED Supplementary protection certificate for pharmaceutical products: no action taken

Free format text: CCP 634, 19981111; NOVARTIS AG

MEDD Supplementary protection certificate for pharmaceutical products: granted

Free format text: CCP 634, 19981111; NOVARTIS AG

TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970324